1 |
Chaudhary, A. K., Yadav, N., Bhat, T. A., O'Malley, J., Kumar, S. and Chandra, D. 2016. A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy. Drug Discov. Today 21, 38-47.
DOI
|
2 |
Chen, D., Peng, F., Cui, Q. C., Daniel, K. G., Orlu, S., Liu, J. and Dou, Q. P. 2005. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front. Biosci. 10, 2932-2939.
DOI
|
3 |
Daskalakis, M., Blagitko-Dorfs, N. and Hackanson, B. 2010. Decitabine. Recent Results Cancer Res. 184, 131-157.
|
4 |
Decker, P. and Muller, S. 2002. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotechnol. 3, 275-283.
DOI
|
5 |
Di Nicuolo, F., Serini, S., Boninsegna, A., Palozza, P. and Calviello, G. 2001. Redox regulation of cell proliferation by pyrrolidine dithiocarbamate in murine thymoma cells transplanted in vivo. Free Radic. Biol. Med. 31, 1424-1431.
DOI
|
6 |
Dorstyn, L., Akey, C. W. and Kumar, S. 2018. New insights into apoptosome structure and function. Cell Death Differ. 25, 1194-1208.
DOI
|
7 |
Farsinejad, S., Gheisary, Z., Ebrahimi Samani, S. and Alizadeh, A. M. 2015. Mitochondrial targeted peptides for cancer therapy. Tumour Biol. 36, 5715-5725.
DOI
|
8 |
Fulda, S. and Debatin, K. M. 2006. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
DOI
|
9 |
Gong, X. G., Lv, Y. F., Li, X. Q., Xu, F. G. and Ma, Q. Y. 2010. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol. Pharm. Bull. 33, 1261-1267.
DOI
|
10 |
Hata, A. N., Engelman, J. A. and Faber, A. C. 2015. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5, 475-487.
DOI
|
11 |
Hengartner, M. O. 2000. The biochemistry of apoptosis. Nature 407, 770-776.
DOI
|
12 |
Hu, Q., Sun, W., Wang, C. and Gu, Z. 2016. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 98, 19-34.
DOI
|
13 |
Iessi, E., Logozzi, M., Mizzoni, D., Di Raimo, R., Supuran, C. T. and Fais, S. 2017. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 8, E2.
DOI
|
14 |
Janssens, S. and Tschopp, J. 2006. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 13, 773-784.
DOI
|
15 |
Kantari, C. and Walczak, H. 2011. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta. 1813, 558-563.
DOI
|
16 |
Katsman, A., Umezawa, K. and Bonavida, B. 2009. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr. Pharm. Des. 15, 792-808.
DOI
|
17 |
Kaufmann, T., Strasser, A. and Jost, P. J. 2012. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 19, 42-50.
DOI
|
18 |
Kroemer, G. and Pouyssegur, J. 2008. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482.
DOI
|
19 |
Malaguarnera, L., Pilastro, M. R., Vicari, L., Dimarco, R., Manzella, L., Palumbo, G. and Messina, A. 2005. Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity. Cancer Invest. 23, 404-412.
DOI
|
20 |
Hajra, K. M. and Liu, J. R. 2004. Apoptosome dysfunction in human cancer. Apoptosis 9, 691-704.
DOI
|
21 |
Mohamed, M. S., Bishr, M. K., Almutairi, F. M. and Ali, A. G. 2017. Inhibitors of apoptosis: Clinical implications in cancer. Apoptosis 22, 1487-1509.
DOI
|
22 |
Moloney, J. N. and Cotter, T. G. 2018. ROS signalling in the biology of cancer. Semin. Cell Dev. Biol. 80, 50-64.
DOI
|
23 |
Nakajima, K., Nangia-Makker, P., Hogan, V. and Raz, A. 2017. Cancer self-defense: An immune stealth. Cancer Res. 77, 5441-5444.
DOI
|
24 |
Nguyen, D. P., Li, J., Yadav, S. S. and Tewari, A. K. 2014. Recent insights into NF- signalling pathways and the link between inflammation and prostate cancer. BJU Int. 114, 168-176.
DOI
|
25 |
Nguyen, H. S., Shabani, S., Awad, A. J., Kaushal, M. and Doan, N. 2018. Molecular markers of therapy-resistant glioblastoma and potential strategy to combat resistance. Int. J. Mol. Sci. 19, E1765.
DOI
|
26 |
Pelicano, H., Carney, D. and Huang, P. 2004. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 7, 97-110.
DOI
|
27 |
Ranganathan, P., Yu, X., Santhanam, R., Hofstetter, J., Walker, A., Walsh, K., Bhatnagar, B., Klisovic, R., Vasu, S., Phelps, M. A., Devine, S., Shacham, S., Kauffman, M., Marcucci, G., Blum, W. and Garzon, R. 2015. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 125, 2689-2692.
DOI
|
28 |
Reubold, T. F. and Eschenburg, S. 2012. A molecular view on signal transduction by the apoptosome. Cell Signal. 24, 1420-1425.
DOI
|
29 |
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. and Bonner, W. M. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868.
DOI
|
30 |
Rybak, P., Hoang, A., Bujnowicz, L., Bernas, T., Berniak, K., Zarebski, M., Darzynkiewicz, Z. and Dobrucki, J. 2016. Low level phosphorylation of histone H2AX on serine 139 ( H2AX) is not associated with DNA double-strand breaks. Oncotarget 7, 49574-49587.
|
31 |
Shao, L., Wu, L. and Zhou, D. 2012. Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor kinase. Transl. Cancer Res. 1, 100-108.
|
32 |
Stresemann, C. and Lyko, F. 2008. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8-13.
DOI
|
33 |
Ta, M. H., Liuwantara, D. and Rangan, G. K. 2015. Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor- activity in autosomal dominant polycystic kidney disease cells. BMC Nephrol. 16, 212.
DOI
|
34 |
Tummers, B. and Green, D. R. 2017. Caspase-8: regulating life and death. Immunol. Rev. 277, 76-89.
DOI
|
35 |
Wadhwa, S. and Mumper, R. J. 2013. D-penicillamine and other low molecular weight thiols: review of anticancer effects and related mechanisms. Cancer Lett. 337, 8-21.
DOI
|
36 |
Wijermans, P. W., Ruter, B., Baer, M. R., Slack, J. L., Saba, H. I. and Lubbert, M. 2008. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk. Res. 32, 587-591.
DOI
|
37 |
Zhang, L., Li, J., Zong, L., Chen, X., Chen, K., Jiang, Z., Nan, L., Li, X., Li, W., Shan, T., Ma, Q. and Ma, Z. 2016. Reactive oxygen species and targeted therapy for pancreatic cancer. Oxid. Med. Cell. Longev. 2016, 1616781.
|
38 |
Zhang, X. Y. and Zhang, P. Y. 2016. Combinations in multimodality treatments and clinical outcomes during cancer. Oncol. Lett. 12, 4301-4304.
DOI
|
39 |
Appleton, K., Mackay, H. J., Judson, I., Plumb, J. A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., Tang, A., Bellenger, K., Mackay, L., Setanoians, A., Schatzlein, A., Twelves, C., Kaye, S. B. and Brown, R. 2007. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25, 4603-4609.
DOI
|
40 |
Arlt, A., Gehrz, A., Muerkoster, S., Vorndamm, J., Kruse, M. L., Folsch, U. R. and Schafer, H. 2003. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22, 3243-3251.
DOI
|
41 |
Birch-Machin, M. A., Russell, E. V. and Latimer, J. A. 2013. Mitochondrial DNA damage as a biomarker for ultraviolet radiation exposure and oxidative stress. Br. J. Dermatol. 169, 9-14.
DOI
|